PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31759770-10 2019 LPS-stimulated production of IL-6 correlated negatively with the parenteral dose of eicosapentaenoic acid + docosahexaenoic acid. Eicosapentaenoic Acid 84-105 interleukin 6 Homo sapiens 29-33 32058033-9 2020 EPA and DHA also significantly lowered production of monocyte chemoattractant protein 1, interleukin (IL)-6 and IL-8. Eicosapentaenoic Acid 0-3 interleukin 6 Homo sapiens 89-107 31455761-10 2019 Plasma EPA level was negatively correlated with IL-6 and TNFalpha levels. Eicosapentaenoic Acid 7-10 interleukin 6 Homo sapiens 48-52 30428424-8 2019 RESULTS: Incubation with EPA and/or DHA attenuated inflammatory response to lipopolysaccharide (LPS) and monocyte co-culture with reduction in post-LPS mRNA expression and protein levels of IL6, CCL2 and CX3CL1. Eicosapentaenoic Acid 25-28 interleukin 6 Homo sapiens 190-193 30900815-4 2019 The in vitro study indicates that supplementation of high-dose DHA+EPA induces the greatest decrease of IL-6 production by PBMCs relative to other groups (p = 0.046). Eicosapentaenoic Acid 67-70 interleukin 6 Homo sapiens 104-108 31059084-0 2019 Eicosapentaenoic acid suppresses angiogenesis via reducing secretion of IL-6 and VEGF from colon cancer-associated fibroblasts. Eicosapentaenoic Acid 0-21 interleukin 6 Homo sapiens 72-76 31059084-9 2019 While LPS stimulation increased VEGF secretion from the two fibroblast types, EPA decreased IL-6 and VEGF secretion from CAFs. Eicosapentaenoic Acid 78-81 interleukin 6 Homo sapiens 92-96 29993265-9 2019 Given that limited trials have focused on EPA or DHA intervention on concentrations of interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha, further RCTs should be explored on these inflammatory factors. Eicosapentaenoic Acid 42-45 interleukin 6 Homo sapiens 87-105 30399404-12 2019 IL-6 response to stress was buffered among high ACE women with high intake of docosahexaenoic acid (DHA) (p = 0.03) and eicosapentaenoic acid (EPA) (p = 0.05). Eicosapentaenoic Acid 120-141 interleukin 6 Homo sapiens 0-4 30399404-12 2019 IL-6 response to stress was buffered among high ACE women with high intake of docosahexaenoic acid (DHA) (p = 0.03) and eicosapentaenoic acid (EPA) (p = 0.05). Eicosapentaenoic Acid 143-146 interleukin 6 Homo sapiens 0-4 25522414-6 2014 RESULTS: We found that venlafaxine and EPA were anti-inflammatory: venlafaxine decreased IL-6, with a trend for decreases of IL-8 and IP-10, while EPA decreased the levels of IL-6, IL-15, IL-1RA, and IP-10. Eicosapentaenoic Acid 39-42 interleukin 6 Homo sapiens 89-93 26340264-7 2015 The adipose tissue and placenta of treated women exhibited a significant decrease in TLR4 adipose and placental expression as well as IL6, IL8, and TNFalpha In vitro, EPA and DHA suppressed the activation of TLR4, IL6, IL8 induced by palmitate in culture of adipose and trophoblast cells. Eicosapentaenoic Acid 167-170 interleukin 6 Homo sapiens 134-137 26340264-7 2015 The adipose tissue and placenta of treated women exhibited a significant decrease in TLR4 adipose and placental expression as well as IL6, IL8, and TNFalpha In vitro, EPA and DHA suppressed the activation of TLR4, IL6, IL8 induced by palmitate in culture of adipose and trophoblast cells. Eicosapentaenoic Acid 167-170 interleukin 6 Homo sapiens 214-217 29735019-6 2018 RESULTS: EPA+DHA therapy had a significant lowering effect on levels of IL-6, IL-1beta and TNF-alpha after 4 weeks of therapy and an even greater lowering effect after 8 weeks of therapy. Eicosapentaenoic Acid 9-12 interleukin 6 Homo sapiens 72-76 25522414-6 2014 RESULTS: We found that venlafaxine and EPA were anti-inflammatory: venlafaxine decreased IL-6, with a trend for decreases of IL-8 and IP-10, while EPA decreased the levels of IL-6, IL-15, IL-1RA, and IP-10. Eicosapentaenoic Acid 39-42 interleukin 6 Homo sapiens 175-179 23361365-0 2013 Docosahexaenoic acid and eicosapentaenoic acid reduce C-reactive protein expression and STAT3 activation in IL-6-treated HepG2 cells. Eicosapentaenoic Acid 25-46 interleukin 6 Homo sapiens 108-112 24122998-8 2013 CONCLUSION: EPA inhibits NF-kappaB activation and IL-6 production in oesophageal cancer cells, their inducing apoptosis. Eicosapentaenoic Acid 12-15 interleukin 6 Homo sapiens 50-54 23890848-4 2013 RESULTS: A combination of EPA and DHA significantly reduced the concentration of IL-8 and IL-6 released into the supernatant compared to untreated controls (p<0.001). Eicosapentaenoic Acid 26-29 interleukin 6 Homo sapiens 90-94 23361365-10 2013 Taken together, our results demonstrate that DHA and EPA are able to reduce IL-6-induced CRP expression in HepG2 cells via an inhibition of STAT3 activation. Eicosapentaenoic Acid 53-56 interleukin 6 Homo sapiens 76-80 23361365-4 2013 The aims of this study were to examine the effect of the n-3 PUFAs, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), on the modulation of IL-6-induced CRP expression and to explore its possible mechanisms. Eicosapentaenoic Acid 100-121 interleukin 6 Homo sapiens 150-154 23361365-4 2013 The aims of this study were to examine the effect of the n-3 PUFAs, docosahexaenoic acid (DHA), and eicosapentaenoic acid (EPA), on the modulation of IL-6-induced CRP expression and to explore its possible mechanisms. Eicosapentaenoic Acid 123-126 interleukin 6 Homo sapiens 150-154 23361365-5 2013 We demonstrated that DHA and EPA inhibited IL-6-induced CRP protein and mRNA expression, as well as reduced CRP promoter activity in HepG2 cells. Eicosapentaenoic Acid 29-32 interleukin 6 Homo sapiens 43-47 23361365-7 2013 Gel electrophoresis mobility shift assays (EMSA) showed that pretreatment with DHA and EPA decreased IL-6-induced STAT3 DNA binding activity but not C/EBPbeta. Eicosapentaenoic Acid 87-90 interleukin 6 Homo sapiens 101-105 23361365-8 2013 By western blot analysis, DHA and EPA inhibited IL-6-induced STAT3 phosphorylation but not ERK1/2 or C/EBPbeta. Eicosapentaenoic Acid 34-37 interleukin 6 Homo sapiens 48-52 22475809-6 2012 Moreover, IL-6 and MCP-1 were more significantly reduced by EPA treatment compared to Agt (IL-6>MCP>Agt). Eicosapentaenoic Acid 60-63 interleukin 6 Homo sapiens 10-14 22475809-6 2012 Moreover, IL-6 and MCP-1 were more significantly reduced by EPA treatment compared to Agt (IL-6>MCP>Agt). Eicosapentaenoic Acid 60-63 interleukin 6 Homo sapiens 91-95 22305406-7 2012 Furthermore, EPA inhibited TNF-alpha-mediated transcription and secretion of interleukin (IL)-6, a key target gene of TNF-mediated NF-kappaB transcriptional activity. Eicosapentaenoic Acid 13-16 interleukin 6 Homo sapiens 77-95 22299617-7 2012 However, whereas DHA reduced only the high IL-1beta/IL-10 ratio, EPA was able to reduce also the IL-6/IL-10 ratio. Eicosapentaenoic Acid 65-68 interleukin 6 Homo sapiens 97-101 21830898-10 2011 The novel intervention strategies being developed for EPA and RA, such as IL-6 and IL-8 signaling blockade, may also be considered for chronic CHIKV arthritis. Eicosapentaenoic Acid 54-57 interleukin 6 Homo sapiens 74-78 23241116-4 2012 IL-1&#223; and IL-6 up-regulation, induced by CyA, was counteracted by the addition of EPA in both protocols; on the contrary, arachidonic acid (AA) magnified CyA the effects. Eicosapentaenoic Acid 91-94 interleukin 6 Homo sapiens 19-23 22293241-4 2012 The present study aimed to investigate the acute and chronic effects of a 2 x 180 mg per day dose of eicosapentaenoic acid (EPA) on interleukin-6 (IL-6) mediated inflammatory response and symptoms associated with DOMS. Eicosapentaenoic Acid 101-122 interleukin 6 Homo sapiens 132-145 22293241-4 2012 The present study aimed to investigate the acute and chronic effects of a 2 x 180 mg per day dose of eicosapentaenoic acid (EPA) on interleukin-6 (IL-6) mediated inflammatory response and symptoms associated with DOMS. Eicosapentaenoic Acid 101-122 interleukin 6 Homo sapiens 147-151 22293241-4 2012 The present study aimed to investigate the acute and chronic effects of a 2 x 180 mg per day dose of eicosapentaenoic acid (EPA) on interleukin-6 (IL-6) mediated inflammatory response and symptoms associated with DOMS. Eicosapentaenoic Acid 124-127 interleukin 6 Homo sapiens 132-145 22293241-4 2012 The present study aimed to investigate the acute and chronic effects of a 2 x 180 mg per day dose of eicosapentaenoic acid (EPA) on interleukin-6 (IL-6) mediated inflammatory response and symptoms associated with DOMS. Eicosapentaenoic Acid 124-127 interleukin 6 Homo sapiens 147-151 22293241-8 2012 In fact, relative to the first baseline, by the third bout of eccentric workout, the EPA group had 103 +- 60% increment in IL-6 levels whereas the placebo group only had 80 +- 26% incremented IL-6 levels (P = 0.020). Eicosapentaenoic Acid 85-88 interleukin 6 Homo sapiens 123-127 22293241-8 2012 In fact, relative to the first baseline, by the third bout of eccentric workout, the EPA group had 103 +- 60% increment in IL-6 levels whereas the placebo group only had 80 +- 26% incremented IL-6 levels (P = 0.020). Eicosapentaenoic Acid 85-88 interleukin 6 Homo sapiens 192-196 21129557-8 2010 RESULTS: Eicosapentaenoic acid effectively reduced LPS-induced or PGE(2)-induced TNF-alpha and IL-6 expression, and increased IL-10 expression significantly when compared with arachidonic acid. Eicosapentaenoic Acid 9-30 interleukin 6 Homo sapiens 95-99 21609530-5 2011 RESULTS: 8-OHDG and IL-6 secretion of HUVECs was significantly increased significantly after incubated with oxLDL for 24 hours which could be significantly attenuated in the presence of tocopherols and EPA (alone or in combination, all P < 0.05) while the strongest inhibition effects were seen with combined use of mixed-tocopherols and EPA. Eicosapentaenoic Acid 202-205 interleukin 6 Homo sapiens 20-24 21609530-5 2011 RESULTS: 8-OHDG and IL-6 secretion of HUVECs was significantly increased significantly after incubated with oxLDL for 24 hours which could be significantly attenuated in the presence of tocopherols and EPA (alone or in combination, all P < 0.05) while the strongest inhibition effects were seen with combined use of mixed-tocopherols and EPA. Eicosapentaenoic Acid 341-344 interleukin 6 Homo sapiens 20-24 21609530-8 2011 CONCLUSION: Combined mixed-tocopherols + EPA use enhanced the inhibiting effects on the secretion of 8-OHDG and IL-6 in oxLDL stimulated HUVECs which might be linked with increased SOD activity and reduced p-PKC activity. Eicosapentaenoic Acid 41-44 interleukin 6 Homo sapiens 112-116 19427777-5 2010 Interleukin (IL)-1beta, IL-6 and tumor necrosis factor-alpha secretion from EPA, DHA and control cells were differentially limited by LPS concentration. Eicosapentaenoic Acid 76-79 interleukin 6 Homo sapiens 24-60 18762411-3 2008 In the present study, EPA inhibited pro-inflammatory cytokine IL-6 production, a characteristic of certain neurodegenerative disorders, in IL-1beta-stimulated C6 glioma cells in dose-dependent fashion. Eicosapentaenoic Acid 22-25 interleukin 6 Homo sapiens 62-66 19885014-5 2009 Results showed that EPA, DHA, or troglitazone significantly reduced COX-2 expression, NF-kappaB luciferase activity, and PGE(2) and IL-6 production in a dose-dependent fashion. Eicosapentaenoic Acid 20-23 interleukin 6 Homo sapiens 132-136 18762411-0 2008 Eicosapentaenoic acid inhibits interleukin-6 production in interleukin-1beta-stimulated C6 glioma cells through peroxisome proliferator-activated receptor-gamma. Eicosapentaenoic Acid 0-21 interleukin 6 Homo sapiens 31-44 18762411-4 2008 EPA down-regulated the expression of IL-6 at mRNA level, indicating that the effect of EPA occurs at the transcriptional level. Eicosapentaenoic Acid 0-3 interleukin 6 Homo sapiens 37-41 18762411-4 2008 EPA down-regulated the expression of IL-6 at mRNA level, indicating that the effect of EPA occurs at the transcriptional level. Eicosapentaenoic Acid 87-90 interleukin 6 Homo sapiens 37-41 18762411-5 2008 In addition, peroxisome proliferator-activated receptor (PPAR) gamma antagonists abolished the inhibitory effect of EPA on IL-1beta-induced IL-6 production, whereas PPARalpha antagonist did not block the inhibitory effect of EPA. Eicosapentaenoic Acid 116-119 interleukin 6 Homo sapiens 140-144 18400717-7 2008 RESULTS: In Caco-2 cells, IL-6 secretion was significantly decreased by troglitazone, DHA, EPA, and GLA. Eicosapentaenoic Acid 91-94 interleukin 6 Homo sapiens 26-30 18541548-8 2008 Changes in the DHA and EPA concentrations were negatively associated with changes in IL-1beta and IL-6 release for all subjects. Eicosapentaenoic Acid 23-26 interleukin 6 Homo sapiens 98-102 17635746-9 2007 A statistically significant negative correlation between TNF-alpha and eicosapentaenoic acid (EPA) (r = -0.497; P < 0.05) and IL-6 and EPA (r = -468; P = 0.03) was found in HD patients before supplementation. Eicosapentaenoic Acid 138-141 interleukin 6 Homo sapiens 129-133 9547608-0 1997 Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Eicosapentaenoic Acid 20-42 interleukin 6 Homo sapiens 97-110 16781858-5 2007 Both EPA and DHA reduced TNF-alpha, IL-1beta and IL-6 mRNA expression. Eicosapentaenoic Acid 5-8 interleukin 6 Homo sapiens 49-53 16781858-7 2007 Furthermore, a low dose (25 microM) of DHA had a greater inhibitory effect than that of EPA on macrophage IL-1beta (P<.01 and P<.04, respectively) and IL-6 (P<.003 and P<.003, respectively) production following 0.01 and 0.1 microg/ml LPS stimulation. Eicosapentaenoic Acid 88-91 interleukin 6 Homo sapiens 157-161 16796997-4 2006 Further, omega-3 eicosapentaenoic acid is capable of down-regulating the production and effect of a number of mediators of cachexia, such as IL-1, IL-6, TNF-alpha and proteolysis-inducing factor. Eicosapentaenoic Acid 9-38 interleukin 6 Homo sapiens 147-151 16234304-6 2006 Lower alpha-linolenic acid was associated with higher C-reactive protein and IL-1ra, and lower eicosapentaenoic acid was associated with higher IL-6 and lower TGFbeta. Eicosapentaenoic Acid 95-116 interleukin 6 Homo sapiens 144-148 15925303-3 2005 EPA, DHA, and AA have negative feedback control on tumor necrosis factor-alpha and IL-6 synthesis. Eicosapentaenoic Acid 0-3 interleukin 6 Homo sapiens 83-87 15925303-4 2005 Hence, EPA, DHA, and AA deficiencies induced by an energy-dense diet increase generation of tumor necrosis factor-alpha and interleukin-6, markers of inflammation that in turn decrease production of endothelial nitric oxide and adiponectin to induce insulin resistance in maternal and fetal tissues. Eicosapentaenoic Acid 7-10 interleukin 6 Homo sapiens 124-137 12720588-12 2003 The threshold of EPA+DHA intake that results in decreased IL-6 production is between 0.44 and 0.94 g/d. Eicosapentaenoic Acid 17-20 interleukin 6 Homo sapiens 58-62 11918718-10 2002 EPA treatment results also in lipid peroxidation and in decreased PGE2 and IL-6 secretion after UVB-irradiation. Eicosapentaenoic Acid 0-3 interleukin 6 Homo sapiens 75-79 9059324-0 1997 Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. Eicosapentaenoic Acid 103-124 interleukin 6 Homo sapiens 156-169 9059324-5 1997 Oral supplementation with eicosapentaenoic acid, in patients with cancer cachexia, resulted in a significant reduction in the serum concentration of the acute-phase protein C-reactive protein (11.0 +/- 4.8 mg/l before eicosapentaenoic acid compared with 0.8 +/- 0.8 mg/l after 4 weeks of eicosapentaenoic acid, P < 0.05), but no significant reduction in the serum concentration of the hepatocyte-stimulating cytokine interleukin-6. Eicosapentaenoic Acid 26-47 interleukin 6 Homo sapiens 420-433 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 142-163 interleukin 6 Homo sapiens 14-27 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 142-163 interleukin 6 Homo sapiens 165-178 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 326-347 interleukin 6 Homo sapiens 14-27 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 326-347 interleukin 6 Homo sapiens 165-178 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 326-347 interleukin 6 Homo sapiens 14-27 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 326-347 interleukin 6 Homo sapiens 165-178 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 326-347 interleukin 6 Homo sapiens 14-27 9059324-6 1997 Production of interleukin-6 by peripheral blood mononuclear cells isolated from patients was significantly reduced after supplementation with eicosapentaenoic acid (interleukin-6 production by peripheral blood mononuclear cells exposed to 10 micrograms of lipopolysaccharide/ml: 10.2 +/- 2.1 ng/ml before supplementation with eicosapentaenoic acid compared with 3.5 +/- 1.7 ng/ml after supplementation, P < 0.05) and supernatants from these cells had reduced potential to stimulate C-reactive protein production by isolated human hepatocytes (hepatocyte C-reactive protein production in response to supernatants from peripheral blood mononuclear cell cultures exposed to 10 micrograms of lipopolysaccharide/ml: 150.4 +/- 18.6 ng/ml before eicosapentaenoic acid versus 118 +/- 14.9 ng/ml after 4 weeks of eicosapentaenoic acid, P < 0.05). Eicosapentaenoic Acid 326-347 interleukin 6 Homo sapiens 165-178 9059324-7 1997 The potential of lipopolysaccharide-stimulated peripheral blood mononuclear cell supernatants to stimulate C-reactive protein production by hepatocytes could be attenuated by neutralizing anti-interleukin-6 antibody in control subjects and in patients before, but not after, treatment with eicosapentaenoic acid. Eicosapentaenoic Acid 290-311 interleukin 6 Homo sapiens 193-206 9059324-9 1997 In conclusion, eicosapentaenoic acid can down-regulate the acute-phase response in patients with pancreatic cancer cachexia and this process is likely to involve suppression of interleukin-6 production. Eicosapentaenoic Acid 15-36 interleukin 6 Homo sapiens 177-190 16781858-4 2007 Pretreatment with 100 microM EPA and DHA significantly decreased lipopolysaccharide (LPS)-stimulated THP-1 macrophage tumor necrosis factor (TNF) alpha, interleukin (IL) 1beta and IL-6 production (P<.02), compared to control cells. Eicosapentaenoic Acid 29-32 interleukin 6 Homo sapiens 180-184 17178390-4 2007 EPA significantly inhibited the release of nitric oxide (NO), prostaglandin E(2) (PGE(2)) and proinflammatory cytokines such as interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha in a dose-dependent manner. Eicosapentaenoic Acid 0-3 interleukin 6 Homo sapiens 152-156 15362934-0 2004 Influence of eicosapentaenoic acid, an omega-3 fatty acid, on ultraviolet-B generation of prostaglandin-E2 and proinflammatory cytokines interleukin-1 beta, tumor necrosis factor-alpha, interleukin-6 and interleukin-8 in human skin in vivo. Eicosapentaenoic Acid 13-34 interleukin 6 Homo sapiens 186-199 11918718-0 2002 Eicosapentaenoic acid, a n-3 polyunsaturated fatty acid differentially modulates TNF-alpha, IL-1alpha, IL-6 and PGE2 expression in UVB-irradiated human keratinocytes. Eicosapentaenoic Acid 0-21 interleukin 6 Homo sapiens 103-107 21432455-4 1997 After EPA intake, at one hour after the load, the change rate of IL-6 decreased to that of before EPA. Eicosapentaenoic Acid 6-9 interleukin 6 Homo sapiens 65-69 21432455-4 1997 After EPA intake, at one hour after the load, the change rate of IL-6 decreased to that of before EPA. Eicosapentaenoic Acid 98-101 interleukin 6 Homo sapiens 65-69 21432455-7 1997 It is suggested that EPA activated IL-6, which was related to the increase of alpha(1)-AGP as an activator of immunity. Eicosapentaenoic Acid 21-24 interleukin 6 Homo sapiens 35-39 33813381-9 2021 IL-6 production was increased following treatment with CDDP, but treatment with EPA decreased IL-6 levels. Eicosapentaenoic Acid 80-83 interleukin 6 Homo sapiens 94-98 7623608-1 1995 The effects of elevated glucose and eicosapentaenoic acid (EPA, C20:5 omega 3) on myo-inositol uptake in human skin fibroblasts (HSF) were evaluated. Eicosapentaenoic Acid 59-62 interleukin 6 Homo sapiens 129-132 7938085-5 1994 Here the authors present data which suggests that PGs including thromboxane B2 (TXB2) and their precursors such as dihomo-gamma linolenic acid (DGLA), arachidonic acid (AA) and eicosapentaenoic acid (EPA) can inhibit T-cell proliferation and influence their ability to secrete IL-2, IL-4, IL-6 and TNF in vitro. Eicosapentaenoic Acid 177-198 interleukin 6 Homo sapiens 289-293 26335632-8 2015 IL-6 and IFNgamma were downregulated in HMGECs treated for 72 h with DHA and EPA. Eicosapentaenoic Acid 77-80 interleukin 6 Homo sapiens 0-4 26335632-9 2015 In general, TNFalpha, IFNgamma and IL-6 levels were decreased after 72 h compared to 24 h in serum containing medium with or without DHA or EPA. Eicosapentaenoic Acid 140-143 interleukin 6 Homo sapiens 35-39 32479111-9 2020 Blood measures of IL-6, but not eosinophils, were significantly associated with EPA, and IL-6 and eosinophils predicted exacerbations in the sample as a whole. Eicosapentaenoic Acid 80-83 interleukin 6 Homo sapiens 18-22 32878792-1 2020 BACKGROUND/AIM: Eicosapentaenoic acid (EPA) inhibits NF-kB activation and IL-6 production in TE-1 esophageal cancer cells. Eicosapentaenoic Acid 16-37 interleukin 6 Homo sapiens 74-78 32878792-1 2020 BACKGROUND/AIM: Eicosapentaenoic acid (EPA) inhibits NF-kB activation and IL-6 production in TE-1 esophageal cancer cells. Eicosapentaenoic Acid 39-42 interleukin 6 Homo sapiens 74-78